PEPTIDESTAT
InvestigationalWeight lossSubcutaneousEvidence 4/5

Efpeglenatide

Also known as: LY3434285

An exendin-4-based GLP-1 receptor agonist conjugated to an antibody Fc fragment that slows clearance and activates the GLP-1 receptor to boost glucose-dependent insulin secretion, slow gastric emptying and reduce appetite.

Read guideBuy / compare source
Efpeglenatide
Drug class
GLP-1 receptor agonist (exendin-4-based)
Primary targets
GLP-1 receptor
Dose reference
Studied in trials at 4 mg or 6 mg once weekly subcutaneously (also 2 mg in dose-ranging); reference ranges from research only, not a recommendation or approved dose.
Half-life
Approximately 5.6 to 7.5 days (single-ascending-dose pharmacokinetic studies)
Developer / origin
Hanmi Pharmaceutical (South Korea); licensed to and trialed by Sanofi, rights returned 2020
Reference year
2021
Evidence score
4/5 - Strong trial evidence but investigational
Evidence 4/5

Strong trial evidence but investigational

Efpeglenatide has genuine phase 3 outcomes evidence: the AMPLITUDE-O trial (NEJM 2021, n=4076) showed weekly subcutaneous dosing reduced major adverse cardiovascular events (7.0% vs 9.2% placebo) and a composite kidney outcome (13.0% vs 18.4%) in high-risk type 2 diabetes, with supporting glycemic and weight data from the broader AMPLITUDE program. However, development was halted by the original sponsor and the agent has no marketing approval.

Investigational compound with human randomized or phase 2/3 evidence.

Evidence basis

  • Randomized, double-blind, placebo-controlled cardiovascular outcomes trial (AMPLITUDE-O, 4076 patients, 28 countries)
  • Multiple phase 2/3 randomized controlled trials in the AMPLITUDE program (M, D, L, S) and a phase 2 study in adults without diabetes
  • Published pharmacokinetic and dose-finding studies
  • Limitation: single-sponsor program halted for business reasons; no regulatory approval and no real-world post-marketing data

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Efpeglenatide guides

Read the matching guide or adjacent research pages for more context.

Efpeglenatide Peptide: Exendin-Based GLP-1 RA and AMPLITUDE-O EvidenceEfpeglenatide is an investigational, exendin-based GLP-1 receptor agonist with positive AMPLITUDE-O cardiovascular and renal outcomes but no marketing approval.Peptides for Weight Loss: GLP-1s, Tirzepatide, Retatrutide and What WorksA broad guide to weight-loss peptides, from approved GLP-1 and dual-incretin medicines to investigational retatrutide, cagrilintide and other research compounds.GLP-1 for Weight Loss: How Well They Work, and What They CostGLP-1 weight-loss drugs produce 8–21% average body-weight reduction in trials. The honest version weighs eligibility, results, cost, side effects, and the rebound after you stop.What Is GLP-1? The Hormone, the Drugs, and Why They WorkGLP-1 is a hormone your gut releases after eating. The agonist drugs amplify that effect — slowing digestion, blunting appetite and steadying blood sugar.

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Retatrutide

LY3437943

4/5
Weight lossInvestigational

Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.

DetailsGuide

Tirzepatide

LY3298176, Mounjaro, Zepbound

5/5
Weight lossApproved

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

DetailsGuide

Semaglutide

Ozempic, Wegovy, Rybelsus

5/5
Weight lossApproved

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

DetailsGuide

Liraglutide

Victoza, Saxenda

5/5
Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

DetailsGuide

Category hub

Open the category page for the full comparison table and FAQ.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Research & educational purposes only

The information on PeptideStat is for educational and research purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use. Always consult a qualified healthcare professional before making any health decisions. Articles may contain affiliate links — we may earn a commission at no extra cost to you.